Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407852 | 0.84 | CACNA2D1 (0.38) | TAAR1HTR2CNPC1MAPTSMN1; SMN2 | |
| SCHEMBL6047619 | 0.83 | CYP1A1 (0.40) | PDE4BMAPK14MAPTTSHRPDE4D | |
| SCHEMBL4804654 | 0.83 | ACHE (0.39) | MAPK10HTR2CNPC1TSHRSMN1; SMN2 | |
| SCHEMBL5887546 | 0.83 | DYRK1A (0.44) | NOTUMSLC6A3SLC6A2HTR2C | |
| SCHEMBL4807843 | 0.80 | MEN1 (0.33) | SLC6A3SLC6A2NPC1TSHRSMN1; SMN2 | |
| SCHEMBL4802145 | 0.79 | AHR (0.41) | NOTUMMAPK10SLC6A3SLC6A2MAPK9 | |
| SCHEMBL4012746 | 0.79 | NOTUM (0.36) | NOTUMNPC1MAPTTSHRSMN1; SMN2 | |
| SCHEMBL9650518 | 0.78 | HTR2C (0.37) | NOTUMTAAR1HTR2CNPC1TSHR | |
| SCHEMBL4014782 | 0.77 | PGR (0.36) | TAAR1HTR2C | |
| SCHEMBL5887377 | 0.77 | MAPT (0.42) | NOTUMNPC1MAPTTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | claimed |
| US-7465808-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-16 | — | — | US | disclosed |
| US-20060014817-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014817-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | NOTUM 4422/4885MAPK10 1116/4885SLC6A3 2192/4885 |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | CCKAR, CCKBR, FFAR1 | NOTUM 2395/4885MAPK10 2580/4885SLC6A3 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.